VERICI DX PLC

Declaration of Voting Results & Voting Rights Announcements • Feb 19, 2024

National Storage Mechanism | Additional information

RNS Number : 6453D

Verici Dx PLC

19 February 2024

Verici Dx plc

("Verici Dx" or the "Company")

Result of General Meeting

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at the general meeting held earlier today (the "GM"), all the resolutions, as set out in the notice of the GM published on 26 January 2024, were duly passed. Resolution 1 was passed as an ordinary resolution and resolution 2 was passed as a special resolution.

The voting results of the GM were as follows:

	In Favour		Against		Withheld
Resolution	Votes	%	Votes	%	Votes
1	68,286,823	99.86	93,862	0.14	13,812
2	68,270,191	99.84	110,494	0.16	13,812

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	Via IR-Connect
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: +44 20 7496 3000
Aubrey Powell / Sam Butcher/ Jalini Kalaravy
IR-Connect	www.ir-connect.co.uk
Lorraine Rees	investors@vericidx.com

About Verici Dx plc www.vericidx.com

Verici is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

ROMGPUCWPUPCGPB